AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32907565 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of HIV positive status by age group
Number of subjects: 1000
Study 32907565 — intervention group
Group type: EXPERIMENTAL
Intervention: On ART by age group
Number of subjects: 1000
Study 32907565 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral suppression by age group
Number of subjects: 1000
Study 32907565 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-90-90 indicators by area type
Number of subjects: 1000
Study 35019901 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume high-intensity interval training (LV-HIT)
Number of subjects: 64
Study 35019901 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume high-intensity interval training (HV-HIT)
Number of subjects: 64
Study 35019901 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 34284802 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus behaviour change therapy
Number of subjects: 0
Study 34284802 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study 32536026 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (RG)
Number of subjects: 77
Study 32536026 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation (MG)
Number of subjects: 77
Study 32536026 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 77
Study 35585981 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion (NMP) with oxygenated banked red blood cell (RBC) based solution for 1h at 36°C
Number of subjects: 0
Study 35585981 — intervention group
Group type: EXPERIMENTAL
Intervention: NMP
Number of subjects: 0
Study 33630675 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (60 minutes at 60% VO2peak)
Number of subjects: 12
Study 33630675 — intervention group
Group type: COMPARATOR
Intervention: Hot water immersion (40.5oC for 60 minutes)
Number of subjects: 12
Study 34821492 — intervention group
Group type: EXPERIMENTAL
Intervention: nomask (nm)
Number of subjects: 16
Study 34821492 — intervention group
Group type: EXPERIMENTAL
Intervention: surgical mask (cm)
Number of subjects: 16
Study 34821492 — intervention group
Group type: EXPERIMENTAL
Intervention: FFP2/N95 mask (ffpm)
Number of subjects: 16
Study 34821492 — intervention group
Group type: COMPARATOR
Intervention: surgical mask (cm) and FFP2/N95 mask (ffpm)
Number of subjects: 16
Study 32005280 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncokompas eHealth self-management application
Number of subjects: 136
Study 32005280 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (no access to Oncokompas for 3 months)
Number of subjects: 136
Study 36976583 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged grief disorder (PGD) diagnosis
Number of subjects: 328
Study 36976583 — intervention group
Group type: COMPARATOR
Intervention: No prolonged grief disorder (PGD) diagnosis
Number of subjects: 328
Study 36976583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cause of death (COVID-19)
Number of subjects: 328
Study 36976583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cause of death (brain hemorrhage)
Number of subjects: 328
Study 34016091 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand hygiene intervention including teacher-led classroom teaching, parental engagement sessions, environmental modifications, and improved handwashing stations.
Number of subjects: 3081
Study 34016091 — intervention group
Group type: COMPARATOR
Intervention: Control group with routine health education.
Number of subjects: 3081
Study 34016091 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined prevalence of Ascaris lumbricoides and Trichuris trichiura infections at end-line survey.
Number of subjects: 3081
Study 34016091 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of Ascaris lumbricoides.
Number of subjects: 3081
Study 34016091 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of Trichuris trichiura.
Number of subjects: 3081
Study 34016091 — intervention group
Group type: EXPERIMENTAL
Intervention: STH infection intensity.
Number of subjects: 3081
Study 32081875 — intervention group
Group type: EXPERIMENTAL
Intervention: MR‐TRYX framework
Number of subjects: 0
Study 32081875 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for pleiotropic pathways
Number of subjects: 0
Study 35230884 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin (40 mg/m2)
Number of subjects: 261
Study 35230884 — intervention group
Group type: COMPARATOR
Intervention: 3-weekly cisplatin (100 mg/m2)
Number of subjects: 261
Study 33401957 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week aerobic and resistance training program (high-intensity interval training and resistance exercises 3 days/week)
Number of subjects: 0
Study 33110130 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% atropine eye drops
Number of subjects: 20
Study 33110130 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% atropine eye drops with myopic defocus
Number of subjects: 20
Study 33110130 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% atropine eye drops with hyperopic defocus
Number of subjects: 20
Study 33110130 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine treatment after 3 and 6 months
Number of subjects: 20
Study 35138402 — intervention group
Group type: EXPERIMENTAL
Intervention: Niclosamide 2 g by mouth daily for 7 days
Number of subjects: 73
Study 35138402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 35138402 — intervention group
Group type: EXPERIMENTAL
Intervention: Niclosamide
Number of subjects: 73
Study 33625509 — intervention group
Group type: EXPERIMENTAL
Intervention: Constituent plus engagement messages
Number of subjects: 789
Study 33625509 — intervention group
Group type: EXPERIMENTAL
Intervention: Constituent-only messages
Number of subjects: 789
Study 33625509 — intervention group
Group type: COMPARATOR
Intervention: Control condition (messages about littering cigarette butts)
Number of subjects: 789
Study 35392902 — intervention group
Group type: EXPERIMENTAL
Intervention: Social reward feature (meal for donation upon quiz completion)
Number of subjects: 30
Study 35392902 — intervention group
Group type: COMPARATOR
Intervention: No social reward feature (control group)
Number of subjects: 30
Study 34108297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cement thickness of 50 µm
Number of subjects: 45
Study 34108297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cement thickness of 100 µm
Number of subjects: 45
Study 34108297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cement thickness of 200 µm
Number of subjects: 45
Study 34108297 — intervention group
Group type: COMPARATOR
Intervention: Cement thickness (general)
Number of subjects: 45
Study 34506986 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac (15 mg every 6 hours)
Number of subjects: 246
Study 34506986 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 246
Study 33792832 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 400 mg sustained release tablet, orally three times daily
Number of subjects: 60
Study 33792832 — intervention group
Group type: COMPARATOR
Intervention: Placebo, orally three times daily
Number of subjects: 60
Study 33231914 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 weeks of knee immobilization
Number of subjects: 28
Study 33231914 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory recovery
Number of subjects: 28
Study 33231914 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 28
Study 33231914 — intervention group
Group type: COMPARATOR
Intervention: Hindlimb suspension for 7 days (HS 7d)
Number of subjects: 28
Study 33231914 — intervention group
Group type: COMPARATOR
Intervention: Weight bearing (WB) control
Number of subjects: 28
Study 33231914 — intervention group
Group type: EXPERIMENTAL
Intervention: Reloading after HS
Number of subjects: 28
Study 32613715 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared beak trimming (IRBT)
Number of subjects: 648
Study 32613715 — intervention group
Group type: COMPARATOR
Intervention: No trimming (NBT)
Number of subjects: 648
Study 32613715 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot-blade beak trimming (HBBT)
Number of subjects: 648
Study 35994126 — intervention group
Group type: EXPERIMENTAL
Intervention: MCAT + CM (collagen matrix)
Number of subjects: 16
Study 35994126 — intervention group
Group type: COMPARATOR
Intervention: MCAT + CTG (connective tissue graft)
Number of subjects: 16
Study 35994126 — intervention group
Group type: EXPERIMENTAL
Intervention: MCAT + CM and CTG (both groups)
Number of subjects: 16
Study 33729674 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 216
Study 33729674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 33729674 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers infected with Trichuris trichiura
Number of subjects: 216
Study 33729674 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-and-heavy intensity infection
Number of subjects: 216
Study 33077475 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (2 mg monthly for 6 months)
Number of subjects: 38
Study 33077475 — intervention group
Group type: COMPARATOR
Intervention: Untreated fellow eyes (control group)
Number of subjects: 38
Study 35403296 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (400 IU per day) for 90 days
Number of subjects: 178
Study 35403296 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment (T2DM group)
Number of subjects: 178
Study 32977846 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual and triplex infections of HIV, Hepatitis B and C viruses among pregnant women
Number of subjects: 0
Study 32977846 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for HIV, HBV or HCV infection at birth and 6 weeks using PCR technique
Number of subjects: 0
Study 35411402 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote antibiotic stewardship program (ASP)
Number of subjects: 9277
Study 33989812 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized low molecular weight heparin (1 mg/kg) with albuterol (2.5 mg) every 20 min for 10 min
Number of subjects: 70
Study 33989812 — intervention group
Group type: COMPARATOR
Intervention: Control group received nebulized albuterol with the same dose
Number of subjects: 70
Study 32726364 — intervention group
Group type: COMPARATOR
Intervention: Traditional resistance training (TRAD)
Number of subjects: 17
Study 32726364 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented eccentric loading (AEL)
Number of subjects: 17
Study 32726364 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented eccentric loading with athletes (AEL-ATH)
Number of subjects: 17
Study 33843831 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-Fr percutaneous catheters (PCs)
Number of subjects: 119
Study 33843831 — intervention group
Group type: COMPARATOR
Intervention: 28-32 Fr chest tubes
Number of subjects: 119
Study 32183861 — intervention group
Group type: EXPERIMENTAL
Intervention: Various intravenous iron preparations
Number of subjects: 40
Study 33784989 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest 2 mg/d for 3 months
Number of subjects: 134
Study 33784989 — intervention group
Group type: COMPARATOR
Intervention: Gonadotropin‐releasing hormone agonist (GnRHa) for 3 months
Number of subjects: 134
Study 32000598 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml of low‐molecular weight Hyaluronic Acid (HA)
Number of subjects: 50
Study 32000598 — intervention group
Group type: COMPARATOR
Intervention: 1 ml of 10mg/ml triamcinolone acetate (CS)
Number of subjects: 50
Study 34500117 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert-annotated images (group 2)
Number of subjects: 10
Study 34500117 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized-morphometry-enriched images (group 3)
Number of subjects: 10
Study 34500117 — intervention group
Group type: COMPARATOR
Intervention: Raw images (group 1)
Number of subjects: 10
Study 34500117 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall accuracy for cirrhosis diagnosis
Number of subjects: 10
Study 34500117 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall accuracy for fibrosis staging
Number of subjects: 10
Study 34500117 — intervention group
Group type: EXPERIMENTAL
Intervention: Marked fibrosis (F?3 or cirrhosis)
Number of subjects: 10
Study 34500117 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination between all F stages in group 2
Number of subjects: 10
Study 34500117 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative predictive value for marked fibrosis
Number of subjects: 10
Study 34500117 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive predictive value for marked fibrosis
Number of subjects: 10
Study 32680462 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs
Number of subjects: 43
Study 32680462 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched)
Number of subjects: 43
Study 33511883 — intervention group
Group type: EXPERIMENTAL
Intervention: β-cryptoxanthin
Number of subjects: 235
Study 33511883 — intervention group
Group type: COMPARATOR
Intervention: None of the carotenoids or retinol
Number of subjects: 235
Study 33094346 — intervention group
Group type: EXPERIMENTAL
Intervention: Documentation of pulmonary nodule characteristics
Number of subjects: 300
Study 33094346 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordance with a thoracic radiologist
Number of subjects: 300
Study 33094346 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up recommendations
Number of subjects: 300
Study 34250947 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation with Transcranial Rotating Permanent Magnet Stimulator (TRPMS)
Number of subjects: 6
Study 34250947 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 6
Study 33875557 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemicraniectomy after ischemic infarction
Number of subjects: 140
Study 35122992 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-resveratrol supplementation (500 mg/day for 4 weeks)
Number of subjects: 20
Study 35122992 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg wheat flour for 4 weeks)
Number of subjects: 20
Study 34642366 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose intermittent radiation treatment (iRT, [Formula: see text] Gy [Formula: see text] 1 every 6 weeks)
Number of subjects: 16
Study 34642366 — intervention group
Group type: COMPARATOR
Intervention: High dose hypofractionated stereotactic radiotherapy (HFSRT, [Formula: see text] Gy [Formula: see text] 5 in daily fractions)
Number of subjects: 16
Study 33549029 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban 0.5 mg/mL
Number of subjects: 60
Study 33549029 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) 1,000 U/mL
Number of subjects: 60
Study 35778355 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamification-based educational intervention (Escape Room, 2 hours)
Number of subjects: 302
Study 35778355 — intervention group
Group type: COMPARATOR
Intervention: Traditional educational programme (1.5 hours session)
Number of subjects: 302
Study 34522625 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Brief Intervention (BI)
Number of subjects: 320
Study 34522625 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face Brief Intervention (BI)
Number of subjects: 320
Study 32683565 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg/day, 3/1 schedule) plus letrozole (2.5 mg/day, continuous)
Number of subjects: 165
Study 32683565 — intervention group
Group type: COMPARATOR
Intervention: Letrozole alone (2.5 mg/day, continuous)
Number of subjects: 165
Study 32683565 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 165
Study 32683565 — intervention group
Group type: COMPARATOR
Intervention: Letrozole alone
Number of subjects: 165
Study 35289096 — intervention group
Group type: EXPERIMENTAL
Intervention: Good communication with good treatment outcome
Number of subjects: 316
Study 35289096 — intervention group
Group type: EXPERIMENTAL
Intervention: Good communication with poor treatment outcome
Number of subjects: 316
Study 35289096 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor communication with good treatment outcome
Number of subjects: 316
Study 35289096 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor communication with poor treatment outcome
Number of subjects: 316
Study 35289096 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect-based trust
Number of subjects: 316
Study 35289096 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition-based trust
Number of subjects: 316
Study 33197808 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 100
Study 33197808 — intervention group
Group type: COMPARATOR
Intervention: Parecoxib
Number of subjects: 100
Study 35856373 — intervention group
Group type: EXPERIMENTAL
Intervention: AS-600 (600 mg of NAC + 80 mg of propolis)
Number of subjects: 46
Study 35856373 — intervention group
Group type: EXPERIMENTAL
Intervention: AS-1,200 (1,200 mg of NAC + 160 mg of propolis)
Number of subjects: 46
Study 35856373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 34021353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 69
Study 34021353 — intervention group
Group type: COMPARATOR
Intervention: Regular Control Group (RCG)
Number of subjects: 69
Study 34986286 — intervention group
Group type: EXPERIMENTAL
Intervention: Three rounds of mass administration of azithromycin (59,852 doses administered)
Number of subjects: 56376
Study 34986286 — intervention group
Group type: COMPARATOR
Intervention: One round of mass administration of azithromycin followed by two rounds of targeted treatment (24,848 doses administered)
Number of subjects: 56376
Study 34986286 — intervention group
Group type: EXPERIMENTAL
Intervention: Three rounds of mass administration of azithromycin (experimental group)
Number of subjects: 56376
Study 34986286 — intervention group
Group type: COMPARATOR
Intervention: One round of mass administration of azithromycin followed by two rounds of targeted treatment (control group)
Number of subjects: 56376
Study 33484699 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 100
Study 33484699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 32169390 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully liquid formulation of trivalent GBS vaccine
Number of subjects: 1050
Study 32169390 — intervention group
Group type: COMPARATOR
Intervention: Lyophilized formulation of trivalent GBS vaccine
Number of subjects: 1050
Study 36067151 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 68
Study 36067151 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 68
Study 33377183 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-sedation
Number of subjects: 344
Study 33377183 — intervention group
Group type: COMPARATOR
Intervention: Sedation
Number of subjects: 344
Study 35642305 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT + IPC
Number of subjects: 43
Study 35642305 — intervention group
Group type: COMPARATOR
Intervention: KT
Number of subjects: 43
Study 35791018 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat, flexible school footwear
Number of subjects: 24
Study 35791018 — intervention group
Group type: COMPARATOR
Intervention: Traditional school footwear
Number of subjects: 24
Study 33621632 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT intervention plus smartwatch app
Number of subjects: 70
Study 33621632 — intervention group
Group type: COMPARATOR
Intervention: iCBT intervention alone
Number of subjects: 70
Study 32925754 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin intervention, at least 3 to 5 times a week for 6 months
Number of subjects: 80
Study 32925754 — intervention group
Group type: COMPARATOR
Intervention: Routine lifestyle intervention (Control)
Number of subjects: 80
Study 35822221 — intervention group
Group type: EXPERIMENTAL
Intervention: Wayfinding aids (colored doors, shapes on the floor, and signage)
Number of subjects: 9
Study 35822221 — intervention group
Group type: COMPARATOR
Intervention: Wayfinding scripts (control group)
Number of subjects: 9
Study 35822221 — intervention group
Group type: EXPERIMENTAL
Intervention: Wayfinding aids
Number of subjects: 9
Study 33430608 — intervention group
Group type: EXPERIMENTAL
Intervention: Just-in-time adaptive interventions delivered via mobile health technologies
Number of subjects: 0
Study 33430608 — intervention group
Group type: EXPERIMENTAL
Intervention: Microrandomized trial design
Number of subjects: 0
Study 35246202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g intravenously every 12 h for 3 days
Number of subjects: 120
Study 35246202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 35246202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 120
Study 33428224 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational social support (MSS) from a nurse
Number of subjects: 225
Study 33428224 — intervention group
Group type: EXPERIMENTAL
Intervention: MSS from a nurse plus significant other support (SOS)
Number of subjects: 225
Study 33428224 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 225
Study 34663491 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1-g loading dose over 10 minutes, then a 3-g maintenance dose over 24 hours)
Number of subjects: 12009
Study 34663491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12009
Study 34663491 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 12009
Study 32961041 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein‐based nutritional formula enriched with leucine and vitamin D
Number of subjects: 140
Study 35317983 — intervention group
Group type: EXPERIMENTAL
Intervention: Video group (watched educational video twice)
Number of subjects: 40
Study 35317983 — intervention group
Group type: COMPARATOR
Intervention: Simulator group (trained using virtual reality simulator)
Number of subjects: 40
Study 34230975 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cultured autologous epidermal cell grafting resuspended in hyaluronic acid (ready-to-use kit)
Number of subjects: 36